Silver Dollar Resources: Fully Funded and Drilling its Flagship Project in the Prolific Mexican Silver Belt

Silver Dollar Resources (CSE: SLV,OTCQB: SLVDF, FSE: 4KW) has launched its campaign on the Investing News Network.

Silver Dollar Resources (CSE: SLV,OTCQB: SLVDF, FSE: 4KW) has an aggressive growth strategy, having acquired its flagship La Joya Silver Project within three months of going public last year. The company’s co-founding shareholder Mr. Sprott now owns approximately 17 percent of shares issued.

Silver Dollar is fully funded to execute its 2021-2022 exploration plans with approximately $10 million in the treasury. The bulk of these funds stem from financing closed last year with lead orders from Mr. Sprott and First Majestic Silver Corp. (TSX: FR, NYSE: AG, FSE: FMV), who is now also one of Silver Dollar’s largest shareholders with approximately 14% of shares issued.

The company boasts a tight share structure with 41,847,237 shares issued, 3,200,000 stock options with an average exercise price of $1.48, and a total of 45,047,237 shares outstanding on a fully diluted basis.

silver dollar resources flagship property

Silver Dollar’s Company Highlights

  • A mineral exploration company with an aggressive growth strategy.
  • Fully funded for drilling on the company’s flagship La Joya Silver Project located in the mining-friendly state of Durango in the heart of the Mexican Silver Belt.
  • Eric Sprott is a co-founding shareholder who currently owns ~17% of shares issued.
  • First Majestic Silver, one of the largest silver producers in Mexico, is also a strategic investor who owns ~14% of the shares issued.
  • The company is led by an experienced management team with 100 years of collective experience in exploration, mining, and the capital markets.
  • The company’s technical advisors include two past recipients of the PDAC Thayer Lindsley Award for their history of world-class mineral deposit discoveries.
  • Evaluating potential spinout of Red Lake gold assets into a separate public company.
  • Actively reviewing additional drill-ready projects in mining-friendly jurisdictions for potential acquisition.

 

Featured
Boreal Metals Corp.   announces it has changed its name to Norden Crown Metals Corp. in accordance with the provisions of the Business Corporations Act . Norden Crown Metals Corp's name reflects the next stage of the new management's corporate strategy, focused on mineral exploration for precious and base metals in "Norden" Scandinavia. The Company's ticker symbol on the TSX-V will be changed to "NOCR."  The name ...

Boreal Metals Corp. (TSXV: BMX) ( Frankfurt : 03E) (OTCQB: BORMF) announces it has changed its name to Norden Crown Metals Corp. ("the Company") (TSXV: NOCR) in accordance with the provisions of the Business Corporations Act ( British Columbia ).

read more Show less
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced it will present data from six company-sponsored studies in support of their respiratory syncytial virus adult vaccine candidate at the Eighth European Scientific Working Group on Influenza meeting . The cornerstone of Janssen's presence at ESWI will be a series of presentations detailing findings from the Phase 2b CYPRESS trial in adults at ...

The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) today announced it will present data from six company-sponsored studies in support of their respiratory syncytial virus (RSV) adult vaccine candidate at the Eighth European Scientific Working Group on Influenza (ESWI) meeting . The cornerstone of Janssen's presence at ESWI will be a series of presentations detailing findings from the Phase 2b CYPRESS trial in adults at increased risk for RSV.

read more Show less
KEYTRUDA Is the First Anti-PD-1L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC Melanoma KEYTRUDA Is Now Approved as Adjuvant Treatment for Patients With Completely Resected Melanoma Across Stage IIB, Stage IIC and Stage III Disease Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved ...

KEYTRUDA Is the First Anti-PD-1/L1 Therapy to Show Recurrence-Free Survival Benefit in the Adjuvant Setting for Stage IIB and IIC Melanoma

KEYTRUDA Is Now Approved as Adjuvant Treatment for Patients (≥12 Years of Age) With Completely Resected Melanoma Across Stage IIB, Stage IIC and Stage III Disease

read more Show less

MARKETS

Markets
TSX20633.27-128.76
TSXV897.13-13.09
DOW34580.08-59.71
S&P 5004538.43-38.67
NASD15085.47-295.85
ASX7241.20+16.00

COMMODITIES

Commodities
Gold1783.440.00
Silver22.540.00
Copper4.27-0.03
Palladium1816.010.00
Platinum936.310.00
Oil66.22-0.28
Heating Oil2.10-0.01
Natural Gas4.09+0.04